XOMA Royalty (XOMA) Other Accumulated Expenses (2011 - 2026)
XOMA Royalty (XOMA) reported Other Accumulated Expenses of $747000.0 for Q1 2026, up 474.62% on a YoY basis from $130000.0 in Q1 2025, and up 598.13% sequentially from $107000.0 in Q4 2025.
XOMA Royalty (XOMA) Other Accumulated Expenses (2011 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 16 years of Other Accumulated Expenses data on file, last reported at $747000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Accumulated Expenses rose 474.62% year-over-year to $747000.0; the trailing twelve-month figure through Mar 2026 stood at $747000.0 (up 474.62% YoY), and the FY2025 full-year result was $107000.0, down 29.14% from the prior year.
- Other Accumulated Expenses climbed to $747000.0 in Q1 2026, from $107000.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $747000.0 in Q1 2026 to a low of $20000.0 in Q2 2022.
- A 5-year average of $194937.5 and a median of $100000.0 in 2023 frame the typical range for Other Accumulated Expenses.
- Across the five-year window, Other Accumulated Expenses jumped 2315.0% in 2024 and dropped 29.14% in 2025, its largest moves.
- Tracing XOMA's Other Accumulated Expenses over 5 years: stood at $40000.0 in 2022, then soared by 125.0% to $90000.0 in 2023, then surged by 67.78% to $151000.0 in 2024, then slipped by 29.14% to $107000.0 in 2025, then surged by 598.13% to $747000.0 in 2026.
- Business Quant data shows XOMA's Other Accumulated Expenses at $747000.0 in Q1 2026, $107000.0 in Q4 2025, and $576000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 747,000.00 |
| Dec 31, 2025 | 107,000.00 |
| Jun 30, 2025 | 576,000.00 |
| Mar 31, 2025 | 130,000.00 |
| Dec 31, 2024 | 151,000.00 |
| Sep 30, 2024 | 445,000.00 |
| Jun 30, 2024 | 483,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 90,000.00 |
| Sep 30, 2023 | 30,000.00 |
| Jun 30, 2023 | 20,000.00 |
| Mar 31, 2023 | 100,000.00 |
| Dec 31, 2022 | 40,000.00 |
| Sep 30, 2022 | 30,000.00 |
| Jun 30, 2022 | 20,000.00 |
| Mar 31, 2022 | 50,000.00 |
| Dec 31, 2021 | 40,000.00 |
| Mar 31, 2021 | 50,000.00 |
| Dec 31, 2020 | 84,000.00 |
| Sep 30, 2020 | 33,000.00 |